Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues

A. Chiti, B. J. Van Graafeiland, G. Savelli, L. Ferrari, E. Seregni, M. R. Castellani, E. Bombardieri

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Neuroendocrine tumours of the gastro-entero-pancreatic tract are an uncommon clinical entity and are believed to arise from the endocrine cells of the gastrointestinal tract. Somatostatin receptor imaging is a diagnostic tool which allows visualization of somatostatin receptor bearing tumours. This scintigraphic procedure is performed with indium-111 labelled octreotide, a somatostatin analogue, chelated with diethylene triamine penta-acetic acid. Radionuclide imaging consists in detecting the biodistribution of somatostatin receptors, normally expressed on the cell surface of neuroendocrine gastro-entero-pancreatic tumours. To date, five types of this receptor have been cloned; indium-111-labelled-pentetreotide can visualize tumours expressing type 2 and 5 receptors. The results of our study, which involved 81 neuroendocrine gastro-entero-pancreatic tumour patients, confirm the superior sensitivity of somatostatin receptor imaging (61%) for primary tumour evaluation with respect to conventional imaging modalities such as computed tomography (40%) or ultrasound (28%). Scintigraphic findings in metastatic liver disease proved to have a sensitivity of 89% for somatostatin receptor imaging, versus 81% and 88% for computed tomography and ultrasound, respectively. In 23% of patients, lesions were found with somatostatin receptor imaging which had been missed using the other diagnostic modalities; in 26% of the patients the therapeutic approach was modified after somatostatin receptor imaging.

Original languageEnglish
JournalItalian Journal of Gastroenterology and Hepatology
Volume31
Issue number7 SUPPL. 2
Publication statusPublished - 1999

Fingerprint

Somatostatin Receptors
Somatostatin
Neoplasms
Tomography
Neuroendocrine Cells
Rubiaceae
Endocrine Cells
Neuroendocrine Tumors
Acetic Acid
Radionuclide Imaging
Gastrointestinal Tract
Liver Diseases

Keywords

  • Neuroendocrine tumours
  • Single photon emission tomography
  • Somatostatin receptor scintigraphy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Chiti, A., Van Graafeiland, B. J., Savelli, G., Ferrari, L., Seregni, E., Castellani, M. R., & Bombardieri, E. (1999). Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues. Italian Journal of Gastroenterology and Hepatology, 31(7 SUPPL. 2).

Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues. / Chiti, A.; Van Graafeiland, B. J.; Savelli, G.; Ferrari, L.; Seregni, E.; Castellani, M. R.; Bombardieri, E.

In: Italian Journal of Gastroenterology and Hepatology, Vol. 31, No. 7 SUPPL. 2, 1999.

Research output: Contribution to journalArticle

Chiti, A, Van Graafeiland, BJ, Savelli, G, Ferrari, L, Seregni, E, Castellani, MR & Bombardieri, E 1999, 'Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues', Italian Journal of Gastroenterology and Hepatology, vol. 31, no. 7 SUPPL. 2.
Chiti, A. ; Van Graafeiland, B. J. ; Savelli, G. ; Ferrari, L. ; Seregni, E. ; Castellani, M. R. ; Bombardieri, E. / Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues. In: Italian Journal of Gastroenterology and Hepatology. 1999 ; Vol. 31, No. 7 SUPPL. 2.
@article{58d89e2233284b5583ef8076861a6eff,
title = "Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues",
abstract = "Neuroendocrine tumours of the gastro-entero-pancreatic tract are an uncommon clinical entity and are believed to arise from the endocrine cells of the gastrointestinal tract. Somatostatin receptor imaging is a diagnostic tool which allows visualization of somatostatin receptor bearing tumours. This scintigraphic procedure is performed with indium-111 labelled octreotide, a somatostatin analogue, chelated with diethylene triamine penta-acetic acid. Radionuclide imaging consists in detecting the biodistribution of somatostatin receptors, normally expressed on the cell surface of neuroendocrine gastro-entero-pancreatic tumours. To date, five types of this receptor have been cloned; indium-111-labelled-pentetreotide can visualize tumours expressing type 2 and 5 receptors. The results of our study, which involved 81 neuroendocrine gastro-entero-pancreatic tumour patients, confirm the superior sensitivity of somatostatin receptor imaging (61{\%}) for primary tumour evaluation with respect to conventional imaging modalities such as computed tomography (40{\%}) or ultrasound (28{\%}). Scintigraphic findings in metastatic liver disease proved to have a sensitivity of 89{\%} for somatostatin receptor imaging, versus 81{\%} and 88{\%} for computed tomography and ultrasound, respectively. In 23{\%} of patients, lesions were found with somatostatin receptor imaging which had been missed using the other diagnostic modalities; in 26{\%} of the patients the therapeutic approach was modified after somatostatin receptor imaging.",
keywords = "Neuroendocrine tumours, Single photon emission tomography, Somatostatin receptor scintigraphy",
author = "A. Chiti and {Van Graafeiland}, {B. J.} and G. Savelli and L. Ferrari and E. Seregni and Castellani, {M. R.} and E. Bombardieri",
year = "1999",
language = "English",
volume = "31",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "7 SUPPL. 2",

}

TY - JOUR

T1 - Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues

AU - Chiti, A.

AU - Van Graafeiland, B. J.

AU - Savelli, G.

AU - Ferrari, L.

AU - Seregni, E.

AU - Castellani, M. R.

AU - Bombardieri, E.

PY - 1999

Y1 - 1999

N2 - Neuroendocrine tumours of the gastro-entero-pancreatic tract are an uncommon clinical entity and are believed to arise from the endocrine cells of the gastrointestinal tract. Somatostatin receptor imaging is a diagnostic tool which allows visualization of somatostatin receptor bearing tumours. This scintigraphic procedure is performed with indium-111 labelled octreotide, a somatostatin analogue, chelated with diethylene triamine penta-acetic acid. Radionuclide imaging consists in detecting the biodistribution of somatostatin receptors, normally expressed on the cell surface of neuroendocrine gastro-entero-pancreatic tumours. To date, five types of this receptor have been cloned; indium-111-labelled-pentetreotide can visualize tumours expressing type 2 and 5 receptors. The results of our study, which involved 81 neuroendocrine gastro-entero-pancreatic tumour patients, confirm the superior sensitivity of somatostatin receptor imaging (61%) for primary tumour evaluation with respect to conventional imaging modalities such as computed tomography (40%) or ultrasound (28%). Scintigraphic findings in metastatic liver disease proved to have a sensitivity of 89% for somatostatin receptor imaging, versus 81% and 88% for computed tomography and ultrasound, respectively. In 23% of patients, lesions were found with somatostatin receptor imaging which had been missed using the other diagnostic modalities; in 26% of the patients the therapeutic approach was modified after somatostatin receptor imaging.

AB - Neuroendocrine tumours of the gastro-entero-pancreatic tract are an uncommon clinical entity and are believed to arise from the endocrine cells of the gastrointestinal tract. Somatostatin receptor imaging is a diagnostic tool which allows visualization of somatostatin receptor bearing tumours. This scintigraphic procedure is performed with indium-111 labelled octreotide, a somatostatin analogue, chelated with diethylene triamine penta-acetic acid. Radionuclide imaging consists in detecting the biodistribution of somatostatin receptors, normally expressed on the cell surface of neuroendocrine gastro-entero-pancreatic tumours. To date, five types of this receptor have been cloned; indium-111-labelled-pentetreotide can visualize tumours expressing type 2 and 5 receptors. The results of our study, which involved 81 neuroendocrine gastro-entero-pancreatic tumour patients, confirm the superior sensitivity of somatostatin receptor imaging (61%) for primary tumour evaluation with respect to conventional imaging modalities such as computed tomography (40%) or ultrasound (28%). Scintigraphic findings in metastatic liver disease proved to have a sensitivity of 89% for somatostatin receptor imaging, versus 81% and 88% for computed tomography and ultrasound, respectively. In 23% of patients, lesions were found with somatostatin receptor imaging which had been missed using the other diagnostic modalities; in 26% of the patients the therapeutic approach was modified after somatostatin receptor imaging.

KW - Neuroendocrine tumours

KW - Single photon emission tomography

KW - Somatostatin receptor scintigraphy

UR - http://www.scopus.com/inward/record.url?scp=0032728205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032728205&partnerID=8YFLogxK

M3 - Article

C2 - 10604128

AN - SCOPUS:0032728205

VL - 31

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 7 SUPPL. 2

ER -